» Articles » PMID: 36505836

A Novel Prediction Model for Pathological Complete Response Based on Clinical and Blood Parameters in Locally Advanced Rectal Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Dec 12
PMID 36505836
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of this study was to investigate whether clinical and blood parameters can be used for predicting pathological complete response (pCR) to neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).

Methods: We retrospectively enrolled 226 patients with LARC [allocated in a 7:3 ratio to a training (n = 158) or validation (n = 68) cohort] who received nCRT before radical surgery. Backward stepwise logistic regression was performed to identify clinical and blood parameters associated with achieving pCR. Models based on clinical parameters (CP), blood parameters (BP), and clinical-blood parameters (CBP) were constructed for comparison with previously reported Tan's model. The performance of the four models was evaluated by receiver operating characteristic (ROC) curve analysis, calibration, and decision curve analysis (DCA) in both cohorts. A dynamic nomogram was constructed for the presentation of the best model.

Results: The CP and BP models based on multivariate logistic regression analysis showed that interval, Grade, CEA and fibrinogen-albumin ratio index (FARI), sodium-to-globulin ratio (SGR) were the independent clinical and blood predictors for achieving pCR, respectively. The area under the ROC curve of the CBP model achieved a score of 0.818 and 0.752 in both cohorts, better than CP (0.762 and 0.589), BP (0.695 and 0.718), Tan (0.738 and 0.552). CBP also showed better calibration and DCA than other models in both cohorts. Moreover, CBP revealed significant improvement compared with other models in training cohort ( < 0.05), and CBP showed significant improvement compared with CP and Tan's model in validation cohort ( < 0.05).

Conclusion: We demonstrated that CBP predicting model have potential in predicting pCR to nCRT in patient with LARC.

Citing Articles

Multiparametric magnetic resonance imaging (MRI)-based radiomics model explained by the Shapley Additive exPlanations (SHAP) method for predicting complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicenter....

Wang Y, Zhang L, Jiang Y, Cheng X, He W, Yu H Quant Imaging Med Surg. 2024; 14(7):4617-4634.

PMID: 39022292 PMC: 11250347. DOI: 10.21037/qims-24-7.


Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Ostojic M, Gavrilovic D, Jankovic R Front Genet. 2023; 14:1245594.

PMID: 37719698 PMC: 10501402. DOI: 10.3389/fgene.2023.1245594.

References
1.
Ono Y, Cates J, Gonzalez R . Can histologic features predict neoadjuvant therapy response in rectal adenocarcinoma?. Pathol Res Pract. 2021; 226:153608. DOI: 10.1016/j.prp.2021.153608. View

2.
Yoo B, Yeo S . Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review. EPMA J. 2017; 8(1):61-67. PMC: 5471803. DOI: 10.1007/s13167-017-0082-x. View

3.
Yang K, Yang S, Liang W, Kuo Y, Lin J, Lin T . Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013; 8:43. PMC: 3599903. DOI: 10.1186/1748-717X-8-43. View

4.
Tan Y, Fu D, Li D, Kong X, Jiang K, Chen L . Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis. Front Oncol. 2019; 9:497. PMC: 6585388. DOI: 10.3389/fonc.2019.00497. View

5.
Pencina M, DAgostino Sr R, DAgostino Jr R, Vasan R . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2007; 27(2):157-72. DOI: 10.1002/sim.2929. View